Skip to main content
Erschienen in: Breast Cancer Research 1/2001

01.02.2001 | Review

The role of bisphosphonates in breast cancer: Direct effects of bisphosphonates on breast cancer cells

verfasst von: Siddhika G Senaratne, Kay W Colston

Erschienen in: Breast Cancer Research | Ausgabe 1/2001

Einloggen, um Zugang zu erhalten

Abstract

In addition to inhibiting bone resorption, bisphosphonates have also been shown to exhibit antitumour effects. In vitro, bisphosphonates inhibit proliferation and induce apoptosis in cultured human breast cancer cells. In addition, bisphosphonate treatment interferes with breast cancer cell adhesion to bone matrix, and inhibits cell migration and invasion. The combination of bisphosphonates with other anticancer drugs such as the taxoids markedly enhances these effects. These newly recognized direct actions of bisphosphonates on breast cancer cells indicate that these agents may have a greater role to play in treatment of patients suffering from cancers with a propensity to metastasize to bone.
Literatur
1.
Zurück zum Zitat Elte JWF, Bijovoet OLM, Cleton FJ, van Oosterom AT, Sleeboom HP: Osteolytic metastases in breast carcinoma. Pathogenesis, morbidity and bisphosphonates treatment. Eur J Cancer Oncol. 1986, 22: 493-500.CrossRef Elte JWF, Bijovoet OLM, Cleton FJ, van Oosterom AT, Sleeboom HP: Osteolytic metastases in breast carcinoma. Pathogenesis, morbidity and bisphosphonates treatment. Eur J Cancer Oncol. 1986, 22: 493-500.CrossRef
2.
Zurück zum Zitat Paterson AHG: Bone metastases in breast cancer, prostate cancer and myeloma. Bone. 1987, 8(suppl 1): S17-S22. Paterson AHG: Bone metastases in breast cancer, prostate cancer and myeloma. Bone. 1987, 8(suppl 1): S17-S22.
4.
Zurück zum Zitat Mundy GR: Mechanism of osteolytic bone destruction. Bone. 1991, 12(suppl 1): S1-S6.CrossRef Mundy GR: Mechanism of osteolytic bone destruction. Bone. 1991, 12(suppl 1): S1-S6.CrossRef
5.
Zurück zum Zitat Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-control trials. Cancer. 2000, 88: 1082-1090. 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.3.CO;2-Q.CrossRefPubMed Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-control trials. Cancer. 2000, 88: 1082-1090. 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.3.CO;2-Q.CrossRefPubMed
6.
Zurück zum Zitat Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MML, Thesing CW, Bijvoet OL: Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. J Bone Miner. 1986, 1: 27-39. Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MML, Thesing CW, Bijvoet OL: Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. J Bone Miner. 1986, 1: 27-39.
7.
Zurück zum Zitat Ryzen E, Martodam R, Troxell M, Benson A, Paterson A, Shepard K, Hicks R: Intravenous etidronate in the management of malignant hypercalcaemia. Arch Intern Med. 1985, 145: 449-452. 10.1001/archinte.145.3.449.CrossRefPubMed Ryzen E, Martodam R, Troxell M, Benson A, Paterson A, Shepard K, Hicks R: Intravenous etidronate in the management of malignant hypercalcaemia. Arch Intern Med. 1985, 145: 449-452. 10.1001/archinte.145.3.449.CrossRefPubMed
8.
Zurück zum Zitat Kanis JA, Urwin GH, Gray RE, Beneton MN, MvCloskey EV, Hamdy NA, Murray SA: Effects of intravenous etidronate on skeletal and calcium metabolism. Am J Med. 1987, 82: 55-70.CrossRefPubMed Kanis JA, Urwin GH, Gray RE, Beneton MN, MvCloskey EV, Hamdy NA, Murray SA: Effects of intravenous etidronate on skeletal and calcium metabolism. Am J Med. 1987, 82: 55-70.CrossRefPubMed
9.
Zurück zum Zitat Lowik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Trsiong-de Groot H, Bijvoet OLM: Migration and phenotypic transformation of osteoclasts precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res. 1988, 3: 185-192.CrossRefPubMed Lowik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Trsiong-de Groot H, Bijvoet OLM: Migration and phenotypic transformation of osteoclasts precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res. 1988, 3: 185-192.CrossRefPubMed
10.
Zurück zum Zitat Hughes DE, MacDonald BR, Russell RGG, Gowen M: Inhibition of osteoclast-like cell formation by bisphosphonates in long term cultures of human bone marrow. J Clin Invest. 1989, 83: 1930-1935.CrossRefPubMedPubMedCentral Hughes DE, MacDonald BR, Russell RGG, Gowen M: Inhibition of osteoclast-like cell formation by bisphosphonates in long term cultures of human bone marrow. J Clin Invest. 1989, 83: 1930-1935.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Toodman GD, Mundy GR, Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995, 10: 1478-1487.CrossRefPubMed Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Toodman GD, Mundy GR, Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995, 10: 1478-1487.CrossRefPubMed
12.
Zurück zum Zitat Selander KS, Monkkonen J, Karhukorpi E, Harkonen P, Hannuniemi R, Vaananen KK: Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol. 1996, 50: 1127-1138.PubMed Selander KS, Monkkonen J, Karhukorpi E, Harkonen P, Hannuniemi R, Vaananen KK: Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol. 1996, 50: 1127-1138.PubMed
13.
Zurück zum Zitat Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995, 55: 3551-3557.PubMed Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995, 55: 3551-3557.PubMed
14.
Zurück zum Zitat Yoneda T, Sasaki A, Dustan C, William PJ, Bauss F, De Clerck YA, Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonates ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest. 1997, 99: 2509-2517.CrossRefPubMedPubMedCentral Yoneda T, Sasaki A, Dustan C, William PJ, Bauss F, De Clerck YA, Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonates ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest. 1997, 99: 2509-2517.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Colucci S, Minielli V, Zambonin G, Grno M: Alendronate acts on bone resorption of human osteoclast-like cells through the inhibition of cell attachment to bone surfaces [abstract]. Bone. 1995, 17: 599-10.1016/8756-3282(96)87948-8.CrossRef Colucci S, Minielli V, Zambonin G, Grno M: Alendronate acts on bone resorption of human osteoclast-like cells through the inhibition of cell attachment to bone surfaces [abstract]. Bone. 1995, 17: 599-10.1016/8756-3282(96)87948-8.CrossRef
16.
Zurück zum Zitat van der Pluijm G, Vloedgraven H, van Beek E, van der Wee, Lowik C, Papapoulos SJ: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. Clin Invest. 1996, 98: 698-705.CrossRef van der Pluijm G, Vloedgraven H, van Beek E, van der Wee, Lowik C, Papapoulos SJ: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. Clin Invest. 1996, 98: 698-705.CrossRef
17.
Zurück zum Zitat Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997, 57: 3890-3894.PubMed Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997, 57: 3890-3894.PubMed
18.
Zurück zum Zitat Magnetto S, Boissier S, Delmas PD, Clezardin P: Additive antitu-mour activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999, 83: 263-269. 10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T.CrossRefPubMed Magnetto S, Boissier S, Delmas PD, Clezardin P: Additive antitu-mour activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999, 83: 263-269. 10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T.CrossRefPubMed
19.
Zurück zum Zitat Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse J-M, Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000, 60: 2949-2954.PubMed Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse J-M, Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000, 60: 2949-2954.PubMed
20.
Zurück zum Zitat Hiraga T, Tanaka S, Yamamoto M, Nakajima T, Ozawa H: Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumour. Bone. 1996, 18: 1-7. 10.1016/8756-3282(95)00428-9.CrossRefPubMed Hiraga T, Tanaka S, Yamamoto M, Nakajima T, Ozawa H: Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumour. Bone. 1996, 18: 1-7. 10.1016/8756-3282(95)00428-9.CrossRefPubMed
21.
Zurück zum Zitat Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PI: Bisphosphonate induced apoptosis of human myeloma cell lines: a novel antitumour activity. Br J Haematol. 1997, 98: 665-672. 10.1046/j.1365-2141.1997.2713086.x.CrossRefPubMed Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PI: Bisphosphonate induced apoptosis of human myeloma cell lines: a novel antitumour activity. Br J Haematol. 1997, 98: 665-672. 10.1046/j.1365-2141.1997.2713086.x.CrossRefPubMed
22.
Zurück zum Zitat Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998, 339: 357-363. 10.1056/NEJM199808063390601.CrossRefPubMed Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998, 339: 357-363. 10.1056/NEJM199808063390601.CrossRefPubMed
23.
Zurück zum Zitat Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000, 82: 1459-1468.CrossRefPubMedPubMedCentral Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000, 82: 1459-1468.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Busch M, Rave-Frank M, Hille A, Duhmke E: Influence of clo-dronate on breast cancer cells in vitro. Eur J Med Res. 1998, 3: 427-431.PubMed Busch M, Rave-Frank M, Hille A, Duhmke E: Influence of clo-dronate on breast cancer cells in vitro. Eur J Med Res. 1998, 3: 427-431.PubMed
25.
Zurück zum Zitat Fleisch H: Bisphosphonates in bone disease, 3rd ed. New York: Parthenon Publishing Group;. 1997 Fleisch H: Bisphosphonates in bone disease, 3rd ed. New York: Parthenon Publishing Group;. 1997
26.
Zurück zum Zitat Fromigue O, Lagneaux L, Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000, 15: 2211-2221.CrossRefPubMed Fromigue O, Lagneaux L, Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000, 15: 2211-2221.CrossRefPubMed
27.
Zurück zum Zitat Senaratne SG, Colston KW: Mechanisms involved in aminobis-phosphonate-induced apoptosis in breast cancer cells [abstract]. Proc Am Assoc Cancer Res. 2001, 42: 2377- Senaratne SG, Colston KW: Mechanisms involved in aminobis-phosphonate-induced apoptosis in breast cancer cells [abstract]. Proc Am Assoc Cancer Res. 2001, 42: 2377-
28.
Zurück zum Zitat Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate Ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001, 61: 4418-4424.PubMed Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate Ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001, 61: 4418-4424.PubMed
29.
Zurück zum Zitat Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001, 84: 1126-1134. 10.1054/bjoc.2001.1727.CrossRefPubMedPubMedCentral Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001, 84: 1126-1134. 10.1054/bjoc.2001.1727.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ: Heterocycle-containing bisphosphonates causes apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res. 1998, 13: 1668-1678.CrossRefPubMed Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ: Heterocycle-containing bisphosphonates causes apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res. 1998, 13: 1668-1678.CrossRefPubMed
31.
Zurück zum Zitat Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ: The bisphosphonates incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998, 58: 5294-5297.PubMed Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ: The bisphosphonates incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998, 58: 5294-5297.PubMed
32.
Zurück zum Zitat Sato M, Gransser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA: Bisphosphonates action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991, 88: 2095-2105.CrossRefPubMedPubMedCentral Sato M, Gransser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA: Bisphosphonates action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991, 88: 2095-2105.CrossRefPubMedPubMedCentral
Metadaten
Titel
The role of bisphosphonates in breast cancer: Direct effects of bisphosphonates on breast cancer cells
verfasst von
Siddhika G Senaratne
Kay W Colston
Publikationsdatum
01.02.2001
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2001
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr412

Weitere Artikel der Ausgabe 1/2001

Breast Cancer Research 1/2001 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.